Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 712,029 | 648,833 | 646,207 | 581,329 | 595,275 |
| Cost of Goods | 130,459 | 125,180 | 137,930 | 128,041 | 130,619 |
| Gross Profit | 581,570 | 523,653 | 508,277 | 453,288 | 464,656 |
| Operating Expenses | 461,577 | 435,371 | 481,928 | 422,804 | 399,709 |
| Operating Income | 120,452 | 88,462 | 27,279 | 30,525 | 65,566 |
| Interest Expense | 3,574 | 3,547 | 6,098 | 3,779 | 3,755 |
| Other Income | 15,258 | 20,632 | -1,854 | 14,923 | 8,999 |
| Pre-tax Income | 132,136 | 105,547 | 19,327 | 41,669 | 70,810 |
| Income Tax | 24,962 | 16,885 | -1,048 | 1,291 | 14,770 |
| Net Income Continuous | 107,174 | 88,662 | 20,375 | 40,378 | 56,040 |
| Net Income | $107,174 | $88,662 | $20,375 | $40,378 | $56,040 |
| EPS Basic Total Ops | 0.56 | 0.47 | 0.11 | 0.21 | 0.30 |
| EPS Basic Continuous Ops | 0.56 | 0.47 | 0.11 | 0.21 | 0.30 |
| EPS Diluted Total Ops | 0.55 | 0.46 | 0.10 | 0.21 | 0.29 |
| EPS Diluted Continuous Ops | 0.53 | 0.45 | 0.11 | 0.21 | 0.29 |
| EPS Diluted Before Non-Recurring Items | 0.77 | 0.49 | 0.26 | N/A | N/A |
| EBITDA(a) | $144,739 | $113,310 | $51,693 | $53,962 | $88,422 |